Impactful Breakthroughs

Impactful Breakthroughs

Download on the App Store

Impactful Breakthroughs episodes

  • Jim McAleer - President & CEO of Alzheimer's Orange County

    How can sponsors spend upwards of $50m on phase 3 trials and still struggle to fill them? Jim McAleer, President and CEO of Alzheimer's Orange County, has an answer that has nothing to do with the protocol.

    On this episode of Impactful Breakthroughs, he speaks with Laura Brencher, VP of Patient Advocacy at Leapcure, about why trusted community organizations are the practical route into clinical trials. Alzheimer's OC is an independent nonprofit providing care consultations, education, support groups and adult day health services to families living with dementia. Jim has run the organization for 22 years and has expanded their reach to now support over 30,000 people a year.

    Jim and Laura cover drug developments which were “always 18 months away” without ever arriving, his hopes for the future of research in the space, and why it’s so critical for patients to be seen as early as possible. You’ll also hear about the many ways Jim and his team holistically support families by connecting them with art, culture, and faith.

    The throughline throughout their conversation is that community organizations are the ones deservedly earning trust from the patients they serve. Treating them as the conduit to successful trials is the fastest honest route to enrollment.


    Timestamps

    00:00 Episode Start

    01:55 How Jim got into the Alzheimer's space

    03:10 What changed in the past 22 years 

    05:30 Dementia as the umbrella term

    07:20 The caregiver experience up close

    11:00 Inside Alzheimer's Orange County's programs

    12:50 Why art, music and faith last longer

    15:20 Connecting families to clinical research

    17:45 What a good sponsor partnership looks like

    20:10 Why families do or don't join trials

    21:55 The hardest parts of running a nonprofit

    25:30 Jim's career highlight and closing reflections

    Key Takeaways

    • It's okay for this to suck. Jim's care managers say this to caregivers who feel guilty about needing a break. He describes spouses of 60 and 70 years watching a partner forget their wedding, and he makes the point that the hardest moment is different for every family. Giving people permission to be tired and out of patience is what makes respite and in-home safeguards something they will actually use.
    • The earlier you face what’s ahead, the more prepared you can be. The pathology for Alzheimer's dementia can sit for 15 or 20 years before symptoms show, and families often read early signs as normal aging. Earlier referral turns a care consultation into a planning conversation, and it tracks with where Jim says the science is focusing on.
    • What we bring to the table is the trust of the people we serve. This is Jim's description of what a sponsor is actually getting in an advocacy partnership. A pharmaceutical company is rarely the organization which families experiencing disease interact with – the organization whose helpline they’ve been calling for years is.
    • Hope is wonderful, false hope is not. Jim ensures his staff corrects coverage that treats a phase 1 mouse study as a potential cure. His team wants families to understand which results are merely a nice headline and which actually deserve their attention. 

    Guest Shoutouts

    • Joshua D. Grill, PhD, Director, UCI MIND, and Professor of Psychiatry & Human Behavior, University of California, Irvine
    • Aaron Ritter, MD, Larkin Family Endowed Chair in Integrative Brain Health and Director, Memory & Cognitive Disorders Program, Hoag Pickup Family Neurosciences Institute
    • Dung Trinh, MD, Chief Medical Officer, Healthy Brain Clinic, and Medical Director, Alzheimer's Orange County

    Resources

    • Connect with guest Jim McAleer on LinkedIn
    • Check out Alzheimer's Orange County
    • Connect with host Laura Brencher on LinkedIn
    • Check out Leapcure
    31 min
  • Leesa Gentry - Chief Clinical Officer at RenovoRX

    While clinical science has made tremendous strides over the last few decades, the clinical operations stringing it all together have barely moved. Today’s guest, Leesa Gentry, can’t believe that gap still exists, and has spent most of her career working on it.

    Leesa is the Chief Clinical Officer at RenovoRX, a Bay Area based life sciences company developing innovative targeted oncology therapies and delivery systems. On this episode of Impactful Breakthroughs, she speaks with Zach Gobst about lean teams, sponsor and CRO relationships, and where AI belongs in clinical research.

    A consistent throughline in their conversation is Leesa’s dedication to fostering human relationships to best advance the research. She believes that CRO dynamics are inherently set up to be adversarial with constant cost and time pressure. With most sponsors “rolling studies into a ball and tossing it over a fence,” her solution is to envelop CROs directly into her teams, empowering them to truly contribute.

    Her take on AI is direct and actionable: It’s here to stay, so figure out how you can use it to clear your head so you can think about what is around the corner, and keep a human in anything that involves patient care.

    Timestamps

    00:00 Episode Start

    02:30 How Leesa went from psychology to clinical research

    05:00 Precision medicine and the end of the linear path

    06:50 What led Leesa to RenovoRx over two other offers

    08:05 A de-risked drug delivered straight to the tumor

    11:15 What a lean clinical team actually needs

    13:55 Why Leesa is often called a cowboy

    20:25 Building one team across cultures

    23:10 Running a Phase III without a CRO

    30:45 Invest in metrics that actually matter

    32:10 What 30 years of revolutions taught Leesa about AI

    36:50 Leesa's mentors and closing reflections

    Key Takeaways

    • Don’t be afraid of the next challenge. Leesa has been called a cowboy on more than one occasion in her career, crediting the name to her habit of taking on work people have already claimed is impossible. If you reframe challenges as opportunities, you never know where you’ll find yourself next.
    • The fact that you launched it means nothing. Leesa is blunt about vanity milestones in clinical technology. Go-live is not a valuable metric, and a dashboard nobody enters data into is still garbage in, garbage out. Be intentional about the products you leverage and the metrics you showcase.
    • The best use of AI right now is clearing your head. Leesa has watched revolutions get oversold before, decentralized trials included, usually because someone threw technology at a problem without understanding how sites and patients would see it. Her practical advice is to use AI on tracking and categorizing so people get their thinking time back, and to keep humans on patient care, patient decisions and ethics.
    • No one will love the work like you do. Leesa recognizes that when outsourcing projects, it’s incredibly difficult to align everyone to row in the same direction. Her solution is to treat CROs, 1099s, and consultants as direct parts of her team, setting clear incentives and allowing them to take full ownership of their contributions.

    Guest Shoutouts

    • Charles D. Wells, MD, Chief Medical Officer and Head of Medical Development, The Gates Medical Research Institute
    • K. Angela Macfarlane, JD, Chief Executive Officer, Perceive Biotherapeutics, Inc.

    Resources

    • Connect with guest Leesa Gentry on LinkedIn
    • Check out RenovoRX
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    40 min
  • Dave Hine - AVP, Financial Services, Suvoda

    What could clinical research learn from an industry where nothing ships until every system works perfectly in tandem with one another? Dave Hine, AVP of Financial Services at Suvoda, brings a deep background in rigorous systems engineering to today’s episode of Impactful Breakthroughs.

    Suvoda is a global clinical trial technology company which provides a unified software platform to manage complex and time-sensitive clinical studies. In today’s conversation, Dave speaks with host Zach Gobst about what an aerospace engineer noticed when he walked into clinical research and could not stop noticing. Dave studied aerospace engineering, worked flight test and computational fluid dynamics software for the Navy, and joined Greenphire in 2018 as its only sales engineer. Today, he leads the team focused on site payments and budgeting.

    The two of them get into interoperability and why it stalls in clinical trials, using military technology as the counterexample. Despite having parts manufactured by a handful of private agencies, each element of an F-18 is federally mandated to work seamlessly together. They also cover how COVID was the moment the public finally understood what a clinical trial was, and what survived from the decentralized trial wave.

    The throughline is a habit most listeners can use directly: treat every process, vendor relationship, and team decision as one system, then ask who is accountable when a piece of it fails. That is the lens Dave brings to site payments, and it holds up as well in a study budget as it does on an aircraft.


    Timestamps

    00:00 Episode Start 

    01:40 Dave’s journey to aerospace engineering

    02:55 Nine years of deep systems experience 

    04:10 What brought Dave to clinical trials in 2018 

    05:20 The importance of interoperability

    08:45 Why Dave stayed in clinical trials 

    10:50 COVID as a turning point for the entire industry 

    12:50 Assume best intent, in both directions 

    16:40 Delegation, standards, and leading a team 

    23:30 Where AI helps and where it should not 

    26:20 Advice, mentors, and thank yous


    Key Takeaways

    • Systems thinking would be an enormous win for patients and clinicians. Dave learned to design for interoperability at the Navy, where every part had to work with one another, regardless of manufacturer. Clinical research has many buyers and no one willing to carry that risk for competitors, and Dave is blunt that incentives often run the wrong way.
    • Risk assessments need to be accessible. Despite being required, Dave points out that risk assessments are still rarely understood well due to overcomplication. In his work today he strips risk down to high, medium, and low, color coded, enabling anyone to get the whole picture from just a glance. 
    • "I would rather have AI edit my summary than me edit an AI summary." Dave uses AI note takers constantly and says they save real time, but his objection is to the order of operations. He argues for writing client-facing summaries yourself first and treating AI as the editor, keeping critical thinking with the human.
    • Assume best intent, in both directions. Dave describes himself as loud and opinionated, and says he now apologizes proactively when he suspects he has landed wrong. This experience has also taught him about the inverse, and he now reminds himself that someone else's decision comes from a different set of experiences, not bad intent.

    Guest Shoutouts

    • Andrew Sutton, VP of Business Development, Conquest Research
    • Benjamin Mell, Director of Site Sales, CRIO
    • Jim Murphy, Operating Partner, The Riverside Company
    • Wayne Baker, Chief Revenue Officer, ValGenesis
    • Kyle Cunningham, Chief Product Officer, RealTime eClinical Solutions
    • Justin Vega, Head of Solutions Consulting, Financial, Suvoda
    • Heather Horville, Solutions Consultant, Suvoda.
    • Andrew Gerrard, Solutions Consultant, Suvoda.

    Resources

    • Connect with guest Dave Hine on LinkedIn
    • Check out Suvoda
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    32 min
  • Dr. Karen Correa - VP Clinical Development Operations, Boehringer Ingelheim

    After 30 years in clinical research, most people would tell you they've seen it all. But for today's guest, Dr. Karen Correa, three decades in the industry has only deepened her conviction that it’s less critical to know everything, and much more important to know everyone. 


    Karen is the VP of Clinical Development Operations at Boehringer Ingelheim, and on this episode of Impactful Breakthroughs she speaks with Zach Gobst about what it really takes to build teams and cultures that deliver for patients.


    The two talk about why culture is the real unmet need in clinical development today. When processes, science, and timelines are all clearly established, company culture is the thing that can't be downloaded or rushed, and yet it's where everything begins and ends. Karen also opens up about the mentors who shaped her character, each pouring something different into her: truth, compassion, curiosity, and courage.


    And when it comes to the inevitable challenges that come with a career of this scope, Karen has a reframe that stays with you. A delay is not a denial. Keep knocking. That no is going to become a yes someday. Because at the end of it all, she's never lost sight of why the work matters, and that's exactly the kind of north star that keeps the best leaders going.


    Timestamps

    00:00 Episode Start

    01:45 How Karen's career in clinical research began

    04:45 Understanding the patient experience from every angle

    05:30 Why culture is the real unmet need in pharma

    09:00 The mentors who shaped Karen's character and courage

    12:30 Reframing challenges as learning opportunities

    15:25 Finding your circle and embracing vulnerability

    16:00 Being intentional about personal growth

    17:15 How Karen is approaching AI today

    19:55 What's energizing Karen about the future of clinical research


    Key Takeaways

    • Culture is the real unmet need. When everyone in the industry already possesses the hard science skills, team culture is the only thing left. Karen believes it’s where everything begins and ends, but yet it’s still an overlooked aspect across the board. 
    • I don't want to know everything. I want to know everyone. Karen's approach to growth and vulnerability is simple. Surround yourself with people who are brighter than you, lean on them when you don't have the answers, and contribute what you know to the circle in return.
    • Be kind to yourself. Karen reframes challenges not as setbacks but as redirections. Moments that force you down a different path you might not have found otherwise. Keep knocking, she says. That no is going to become a yes someday.
    • Keep your leadership authentic. Karen credits many mentors for helping to build her into the leader she is today. She says “Leadership is about knowing who you are and refusing to compromise on that foundation.”
    • Curiosity is a form of humility. Karen reminds us all to stay curious and teachable throughout our careers. “The best leaders never assume that they've arrived. They stay open, stay hungry, and stay teachable.”

    Guest Shoutouts

    • Ubavka DeNoble MD, Corporate Vice President, Patient Technology Solutions/Growth, PAREXEL
    • Christine Enciso, Vice President, Development Services and Operational Excellence, Regeneron
    • Jeremy Chadwick, Chief Operating Officer, Kymera Therapeutics
    • Brian Meltzer MD, Vice President, Clinical Research, Alexion Pharmaceuticals, Inc.

    Resources

    • Connect with guest Karen Correa on LinkedIn
    • Check out Boehringer Ingelheim
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    24 min
  • Kate Stratton - Executive Director, Lipodystrophy United

    What does it look like to truly amplify the voices of those suffering from a rare disease, especially when you yourself have such a personal connection? On this episode of Impactful Breakthroughs, Zach Gobst sits down with Kate Stratton, Executive Director of Lipodystrophy United, a patient-driven global community dedicated to improving the lives of those affected by lipodystrophy through advocacy, community, and research.


    Kate shares how her empathetic approach to patient advocacy was shaped. From her own mother’s experience navigating a 37-year diagnostic odyssey, to her experiences working with Planned Parenthood and asylum seekers, she emphasizes the importance of direct conversations rather than assumptions. You’ll also hear Kate’s journey navigating imposter syndrome and her advice for any young entrepreneurs out there looking to make their ideas a reality. 


    This conversation is a testament to what happens when personal experience, genuine empathy, and a refusal to wait for permission all come together in one person.


    Timestamps

    00:00 Episode Start

    01:55 Kate's personal path into patient advocacy

    04:15 Lipodystrophy and how it affects the body

    07:00 The common thread across all advocacy work

    09:25 Patient voices matter most

    12:15 Ensuring no one gets put in the wrong box

    14:45 Being a young leader and navigating imposter syndrome

    16:20 What Kate has learned from openness and collaboration

    19:15 What's next for Lipodistrophy Untied

    21:45 Kate’s advice for younger generations


    Key Takeaways

    • One patient's experience is not a population. Kate is emphatic that true patient-centricity means continuously expanding the network of voices you listen to rather than relying on a single story or a token representative. After two years leading Lipodystrophy United, she still learns something new every time she speaks with a community member.
    • Amplify, don't replace. Kate's approach to advocacy across immigration, health policy, and now rare disease, has always been the same: listen deeply, then lift others' voices rather than substituting your own. It's a philosophy that builds trust and creates lasting change.
    • Just decide to do it. If you believe you can do something, you probably can. Surrounding yourself with people who are doing unconventional things and not waiting for external validation is what separates those who make an impact from those who talk about it.
    • Age is not a barrier to impact. Kate has seen firsthand how quickly change can be made. At 23 she’s already expanded her team, published research, raised over $250,000 for the organization, and secured an FDA meeting for patients.

    Guest Shoutouts

    • Andra Stratton, President and Co-Founder of Lipodystophy United
    • Sabine Tilp, Journalist, Patient Advocate and leader of the German Lipodystrophy Network

    Resources

    • Connect with guest Kate Stratton on LinkedIn
    • Check out Lipodystrophy United
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    26 min
  • Francesca Barone - Chief Scientific Officer, Candel Therapeutics

    How far can curiosity take you when you’re not afraid of the unknown? For today’s guest, Francesca Barone, it led her across continents and disciplines as she navigated her way to the forefront of cancer immunotherapy. Francesca is the Chief Scientific Officer at Candel Therapeutics, and on this episode of Impactful Breakthroughs she speaks with Zach Gobst about how Candel is developing multimodal biological immunotherapies to help patients fight cancer.


    Francesca shares the driving force, her “backpack theory,” behind the journey she’s taken. Rather than settling into comfort, she believes every few years you should pack up what you've learned and head toward a new challenge entirely. It’s a belief that has carried her from academic rheumatology to leading cutting-edge oncology drug development, navigating language barriers, cultural shifts, and an industry that wasn't yet ready to believe in what her team was building. 


    She also shares what it took to push Candel's novel intratumoral delivery approach through years of skepticism, why her physician background has been her greatest superpower in biotech, and what it really means to keep patients at the center even when your work may feel far removed. Behind every compassionate use request, every data point, and every clinical trial, there is a patient and a family. And for Francesca, that's always been reason enough to keep going.


    Timestamps

    00:00 Episode Start

    01:45 Why Francesca moved from academia to biotech

    03:55 The power of stretching beyond your comfort zone

    09:30 You're only as good as your team

    10:15 Candel's novel approach to fighting cancer

    13:35 Overcoming skepticism and remaining committed

    17:05 The human side of drug development

    19:20 A patient stories that say it all

    23:25 Mentors who shaped Francesca’s journey

    29:30 Closing reflections on purpose and impact


    Key Takeaways

    • Explore curiosity throughout your career. Francesca's guiding philosophy is simple: every few years, pack up what you know and head somewhere new. The discomfort of starting over in a new field, a new country, or a new challenge is exactly where the best growth happens.
    • Patients are better at designing trials than we are. When patients are truly embedded in your drug development process, you avoid mistakes you wouldn't have seen coming. Assuming you already know what will serve patients best is a trap that leads science in the wrong direction
    • Find your conviction. Candel's intratumoral delivery was once met with investor skepticism and industry doubt. Now major pharma companies are building similar programs. Believing in your data when others don't is part of the job.
    • Steady leadership is contagious. Francesca credits Candel CEO Paul Peter Tak with modeling a calm, thoughtful leadership style that she has worked to channel in herself, particularly in turbulent moments. In science and life, the ability to stay grounded in a storm makes everyone around you steadier too.

    Guest Shoutouts

    • Guido Valesini, Professor of Rheumatology at Sapienza University of Rome
    • Christopher Buckley, Kennedy Trust Feldmann Maini Professor of Translational Medicine at University of Oxford
    • Paul Peter Tak, President, CEO, and Board Director of Candel Therapeutics 

    Resources

    • Connect with guest Francesca Barone on LinkedIn
    • Check out Candel Therapeutics
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    32 min
  • Becky Weber - EVP of Sales, Lunit

    What happens when a career built on the cutting edge of health technology suddenly extends to become deeply personal? On this episode of Impactful Breakthroughs, Zach Gobst is joined by longtime friend Becky Weber, the EVP of Sales at Lunit Cancer Screening. Lunit, formerly Volpara Health, provides AI-powered software for breast cancer screening and early detection, supporting over one million screenings annually.


    With 20 years working at the intersection of health and technology, Becky walks through her journey from shadowing surgeries as a teenager, to helping build HealthKit at Apple, to ultimately joining the team at Lunit following her own breast cancer diagnosis. You’ll hear her share why mission alignment has proven to be the secret in Lunit’s successful merger with Volpara, what she believes it’ll take to navigate regulatory hurdles safely in the AI era, and how her perspective on life and career has completely pivoted. 


    Equal parts personal story and industry insight, this conversation serves as a reminder that the most powerful driver in health technology is the reason behind it.


    Timestamps

    00:00 Episode Start

    01:35 Becky's journey in health tech

    04:05 A breast cancer diagnosis which changed it all

    08:45 Following your passions

    12:09 Prioritizing team impact over personal politics

    13:45 Why startups beat big companies for the puzzle-solvers

    14:45 Lunit's two-sided platform and the AI difference

    17:10 The interval cancer study proving their work

    20:25 Hiring for personal connection to the mission

    22:10 Mentors who made a difference

    22:50 The convergence of research, product, and diagnosis

    25:00 AI, regulation, and the rocket ship problem


    Key Takeaways

    • Personal connection drives performance. Just like in her own story, Becky has found that the candidates with personal ties to breast cancer consistently outperform those who don’t.
    • Data is already changing what's possible. Lunit's AI would have reduced confirmed interval cancers by a third in a study out of Mass General Brigham, meaning women who would have faced late-stage diagnoses could have been found earlier. That's not a future promise, it's happening now.
    • Drop the politics, focus on the outcome. Becky is candid about how her perspective on work shifted after her diagnosis. Empire building, org size, and resume padding simply stopped mattering. What replaced it was something much simpler and more freeing – to get the best result for the patient.
    • The guidelines were built for a train, not a rocket ship. As Becky put it, the regulatory frameworks governing AI in medicine were designed for a different era. Figuring out how to move fast responsibly is the real challenge ahead.

    Guest Shoutouts

    • Dr. Manisha Bahl, Radiologist at Massachusetts General Hospital
    • Teri Thomas, CEO of Mach7 Technologies & Former CEO of Volpara Health / Lunit Cancer Screening 

    Resources

    • Connect with guest Becky Weber on LinkedIn
    • Check out Lunit Cancer Screening
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    27 min
  • Jennifer Good - President & CEO, Trevi Therapeutics

    When all of the experts around you say it’s impossible to move the needle forward, how do you still maintain commitment to your research and patients? On the very first episode of Impactful Breakthroughs, Zach Gobst is joined by Jennifer Good, the President & CEO of Trevi Therapeutics, to explore why she has dedicated the past fifteen years to tackling one of medicine’s most overlooked conditions: chronic cough.


    Jennifer traces her path from running Pennwest Pharmaceuticals to negotiating a promising compound out of an acquisition and building Trevi from her kitchen table into the $2B public company it is today. She shares how a background in chronic pain research gave her and Co-Founder Dr. Thomas Sciascia a uniquely brain-centered lens on cough, and why listening closely to patients led them to double down on IPF when key opinion leaders told them to walk away. Equal parts science story and entrepreneurial journey, this conversation is a candid look at what perseverance, patient focus, and the willingness to evolve really look like in biotech.


    Timestamps

    00:00 Episode Start

    03:00 Starting Trevi Therapeutics from the kitchen table

    05:45 Advice for early entrepreneurs

    07:30 Setting checkpoints and sticking to them

    08:45 What was missing on chronic cough and IPF

    12:45 How chronic pain research unlocked a new view of cough

    18:45 Where Trevi fits into the patient experience

    22:45 Reflections on her 15-year journey

    25:30 Evolving the team as the company grows

    32:00 Giving back through rare disease boards and community

    34:45 Mentorship shoutouts


    Key Takeaways

    • The brain matters in cough. While the broader industry was targeting peripheral receptors in the lung, Trevi's neurology-rooted perspective led them to the brain, setting their data apart when everything else failed.
    • Stay close to the patient. Jennifer's most powerful moment came from a patient advisory board member who couldn't finish her grocery shopping because of a coughing attack. That story is what drives the work and keeps the north star clear.
    • Give yourself a checkpoint, not a cliff. As Jennifer put it, setting a defined window to test your idea, with real deliverables, takes the daily anxiety out of entrepreneurship. You're not on a never-ending rolling stone, you're running an experiment.
    • Roles change, people change, and that’s okay. One of Jennifer's hardest and most important leadership lessons: the person who was right for the company at three people may not be the right person at forty-five. Honest self-reflection applies to the whole team, including the CEO.

    Guest Shoutouts

    • David Meeker MD, Chairman, President, and Chief Executive Officer of Rhythm Pharmaceuticals
    • Stuart Falber, Partner and Co-Chair of WilmerHale's Life Sciences Practice
    • Paul Freiman, Former Chairman of the Board of Penwest

    Resources

    • Connect with guest Jennifer Good on LinkedIn
    • Check out Trevi Therapeutics
    • Connect with host Zach Gobst on LinkedIn
    • Check out Leapcure
    36 min
  • Dan Ignaszewski - Executive Director, National Alliance for Eye and Vision Research

    What does it take to protect the research that could one day save your sight? On this episode of Leap Together, Zach Gobst is joined by Dan Igniewski, Executive Director of the National Alliance for Eye and Vision Research (NAEVR) and the Alliance for Eye and Vision Research (AEVR). With over 20 years in government affairs and patient advocacy, Dan has become one of Washington's most persistent voices for vision research funding, and today's conversation shows exactly why that work matters.


    Dan traces his path from early healthcare policy work to championing the National Eye Institute's independence on Capitol Hill, sharing how vision science is quietly leading some of medicine's most exciting frontiers, from the first FDA-approved gene therapy to AI-powered diagnostics and stem cell breakthroughs. He also unpacks NAEVR's “See What Matters” campaign, the mechanics of effective coalition building, and what it really takes to align patients, providers, researchers, and industry around a single message when federal funding is on the line.


    Timestamps

    00:00  Episode start

    01:45  Dan's background and path to advocacy

    03:55  What makes vision research unique

    05:45  Parallels between policy and clinical research

    06:55  Bipartisan support for NIH and the National Eye Institute

    08:00  Career inflection points and advocacy wins

    11:00  The See What Matters campaign

    14:50  Shared challenges in patient engagement

    16:55  What makes advocacy most effective

    19:40  Mentorship and career guidance

    23:15  The power of persistence and confidence

    25:30  Closing thoughts


    Key Takeaways

    • Coalition is everything. When patients, providers, researchers, and industry align around a shared message, Congress listens. No single organization can move policy alone.
    • Vision research punches above its weight. From the first FDA-approved gene therapy to stem cell and AI advances, vision scientists have quietly been leading the broader medical research field for decades.
    • Don't wait to be taken seriously. As Dan once heard from a colleague: "You've been in the decision-making rooms for years, why do you think suddenly at 30 it's gonna change?" Show up, know your value, and make your point.
    • Vigilance is ongoing. Even with recent wins protecting NIH funding, Dan reminds us that staying engaged and vocal is a continuous responsibility, not a one-time effort.

    Resources

    • Connect with Dan Igniewski on LinkedIn
    • Check out the See What Matters Campaign
    • Check out the National Alliance for Eye and Vision Research
    • Connect with Zach Gobst on LinkedIn
    • Check out Leapcure
    24 min
  • Dr. Joshua Ortiz-Guzman - Director of Clinical Research and Translational Scientist

    What happens when a neuroscientist follows his curiosity from the brain to the soil, and then to the stars? In this episode of Leap Together, Zach Gobst sits down with Dr. Joshua Ortiz-Guzman, a gene therapy engineer and developmental neuroscientist turned clinical research leader, industrial biotechnologist, and soil health innovator. Joshua's work spans an unusually wide range: building clinical research capacity in underserved El Paso, Texas; developing microbial biochar technologies that restore degraded soils; banking stem cells to rigorously track regenerative medicine outcomes; and orienting all of it toward a long-term vision of human longevity and space exploration.


    This episode explores how environmental health and human health are deeply interconnected, and why that connection is chronically underappreciated in clinical research. Joshua shares how his PhD on brain-driven food intake led him down a rabbit hole from farm-to-table agriculture to emerging environmental contaminants like PFAS ("forever chemicals"), and why he believes the clinical research community can't fully understand drug outcomes without accounting for the environments patients live in.


    He also reflects candidly on the challenges of building a research program from scratch in El Paso, a predominantly Spanish-speaking, medically underserved region where providers are overstretched, community trust requires intentional outreach, and groups like the Medical Center of the Americas are making real strides through “promotoras” led education. Joshua's journey from academic idealism to real-world business acumen, from soil pilots in Chihuahua and Colombia with Aurum Tech to a Florida-based stem cell bank called Prodigy Cells, is a rare example of evidence-first rigor applied consistently across human health and environmental systems.

    47 min

About Impactful Breakthroughs

From the publisher's feed

This is Impactful Breakthroughs, the podcast where we highlight top leaders driving breakthroughs in clinical research and life sciences.